Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Innate Pharma (NASDAQ:IPHA), Fate Therapeutics (NASDAQ:FATE), Kyverna Therapeutics (NASDAQ:KYTX), Alector (NASDAQ:ALEC) and Lyell Immunopharma (NASDAQ:LYEL).
Adaptimmune Therapeutics has a consensus price target of $3.86.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $0.579 last updated January 17, 2025 at 6:40 PM EST.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q4 earnings are confirmed for Wednesday, March 5, 2025.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.